您好,欢迎访问中山大学肿瘤防治中心官方网站!
内部网 职工邮箱 图书馆 OA系统 医生门户 English
院士风采 首席专家 临床专家 科研学者 客座教授 人才名录
首页
  • 朱孝峰

    职务:华南肿瘤学国家重点实验室副主任
    职称:研究员,博士生导师
    专长:肿瘤信号转导、自噬调控与靶向药物研究
      朱孝峰,男,1970年9月出生,博士, 教授,博士生导师。中山大学肿瘤防治中心华南肿瘤学国家重点实验室副主任,主要从事肿瘤信号转导、自噬调控与靶向药物研究。
      2000年在美国乔治城大学癌症中心学习,2002年获中国药理学会施维雅青年药理学工作者奖,2007年入选教育部新世纪优秀人才支持计划,现为广东省抗癌协会抗肿瘤药物专业委员会候任主任委员,广东省肿瘤药理专业委员会主任委员,Chin J Cancer、Front Pharmacol、Advances in Therapy等杂志编委。
      先后承担国家自然科学基金重点项目1项,面上项目7项、973计划课题(组长)1项、973计划课题(骨干)1项以及863计划、省市科技项目等多项课题,发表SCI收录论文90余篇,以通讯作者发表SCI收录论文40余篇包括Nature Communications, Leukemia, Autophagy, Oncogene(4篇)等国际著名杂志,主编人民卫生出版社出版的《信号转导与疾病》和广东科技出版社出版《肿瘤生物治疗学》等专著,申请新药发明专利九项,其中五项已获授权,研发的抗肿瘤新药阿诺宁注射液已转让企业开发。
      朱孝峰,男,1970年9月出生,博士, 教授,博士生导师。中山大学肿瘤防治中心华南肿瘤学国家重点实验室副主任,主要从事肿瘤信号转导、自噬调控与靶向药物研究。2000年在美国乔治城大学癌症中心学习,2002年获中国药理学会施维雅青年药理学工作者奖,2007年入选教育部新世纪优秀人才支持计划,现为广东省抗癌协会抗肿瘤药物专业委员会候任主任委员,广东省肿瘤药理专业委员会主任委员,中国抗癌协会抗癌药物专业委员会委员,中国药理学会肿瘤药理及化疗专业委员会委员,Chin J Cancer、Front Pharmacol、Advances in Therapy等杂志编委。先后承担国家自然科学基金重点项目1项,面上项目7项、973计划课题(组长)1项、973计划课题(骨干)1项以及863计划、省市科技项目等多项课题,发表SCI收录论文90余篇,以通讯作者发表SCI收录论文40余篇包括Nature Communications, Leukemia, Autophagy, Oncogene(4篇)等国际著名杂志,主编人民卫生出版社出版的《信号转导与疾病》和广东科技出版社出版《肿瘤生物治疗学》等专著,申请新药发明专利九项,其中五项已获授权,研发的抗肿瘤新药阿诺宁注射液已转让企业开发。
     
    近年以通讯作者发表的主要论文: 
     
      1. Ting Sun, Xuan Li, Peng Zhang, Wen-Dan Chen, Hai-Liang Zhang, Dan-Dan Li, Rong Deng, Xiao-Jun Qian, Lin Jiao, Jiao Ji, Yuan-Tian Li, Rui-Yan Wu, Yan Yu, Gong-Kan Feng, Xiao-Feng Zhu*. Acetylation of Beclin 1 inhibits autophagosome maturation and promotes tumour growth. Nat Commun. 2015; 6: 7215.
      2. Jing-Hong Chen, Peng Zhang, Wen-Dan Chen, Dan-Dan Li, Rong Deng, Xuan Li, Jiao Ji, Gong-Kan Feng, Yi-Xin Zeng, Jian-Wei Jiang, Xiao-Feng Zhu*. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to topotecan in cancer cells. Autophagy, 2015; 11(2): 239-52
      3. Xu XL, Cheng H, Tang MS, Zhang HL, Wu RY, Yu Y, Li X, Wang XM, Mai J, Yang CL, Jiao L, Li ZL, Zhong ZM, Deng R, Li JD, Zhu XF*. A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer. Oncotarget, 2016 Dec 22. doi: 10.18632/oncotarget.14100. [Epub ahead of print]
      4. Huang L, Lan WJ, Deng R, Feng GK, Xu QY, Hu ZY, Zhu XF*, Li HJ. Additional New Cytotoxic Triquinane-Type Sesquiterpenoids Chondrosterins K-M from the Marine Fungus Chondrostereum sp. Mar Drugs, 2016;14(9). pii: E157.
      5. Jiao L, Li DD, Yang CL, Peng RQ, Guo YQ, Zhang XS, Zhu XF*. Reactive oxygen species mediate oxaliplatin-induced epithelial-mesenchymal transition and invasive potential in colon cancer. Tumour Biol. 2016;37(6):8413-23.
      6. Lu QP, Chen WD, Peng JR, Xu YD, Cai Q, Feng GK, Ding K, Zhu XF*, Guan Z. Antitumor activity of 7RH, a discoidin domain receptor 1 inhibitor, alone or in combination with dasatinib exhibits antitumor effects in nasopharyngeal carcinoma cells. Oncol Lett, 2016;12(5):3598-3608.
      7. Xiao-jun Qian, Yun-tian Li, Yan Yu, Yang Fen, Rong Deng, Jiao Ji, Lin Jiao, Xuan Li, Rui-Yan Wu, Wen-Dan Chen, Gong-Kan Feng, Xiao-Feng Zhu*. Inhibition of DNA Methyltransferase as a Novel Therapeutic Strategy to Overcome Acquired Resistance to Dual PI3K/mTOR Inhibitors. Oncotarget. 2015; 6(7): 5134-46
      8. Juan Qin, Jiao Ji, Rong Deng, Jun Tang, Fen Yang, Gong-Kan Feng, Wen-Dan Chen, Xiao-Qi Wu, Xiao-Jun Qian, Shao-Hua Chang, Ke Ding, Xiao-Feng Zhu*. DC120, a novel AKT inhibitor, preferentially inhibits nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2 expression. Oncotarget. 2015; 6(9):6944-58
      9. Yun-Tian Li, Xiao-Jun Qian, Yan Yu, Zhen-Hua Li, Rui-Yan Wu, Jiao Ji, Lin Jiao, Xuan Li, Peng-Fei Kong, Wen-Dan Chen, Gong-Kan Feng, Rong Deng, Xiao-Feng Zhu*. EGFR tyrosine kinase inhibitors promote pro-caspase-8 dimerization that sensitizes cancer cells to DNA-damaging therapy. Oncotarget. 2015 Apr 29. [Epub ahead of print]
      10. Yang F, Deng R, Qian XJ, Chang SH, Wu XQ, Qin J, Feng GK, Ding K, Zhu XF*. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer. Cell Death Dis. 2014;5:e1114.
      11. He JH, Liao XL, Wang W, Li DD, Chen WD, Deng R, Yang D, Han ZP, Jiang JW, Zhu XF*. Apogossypolone, a small-molecule inhibitor of Bcl-2, induces radiosensitization of nasopharyngeal carcinoma cells by stimulating autophagy. Int J Oncol, 2014:45(3): 1099-108.
      12. Yang F, Qian XJ, Qin W, Deng R, Wu XQ, Qin J, Feng GK, Zhu XF*. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma. PLoS One. 2013;8(3):e59879
      13. Xiao-Yue Zhang, Xiao-Qi Wu, Rong Deng, Ting Sun, Gong-Kan Feng, Xiao-Feng Zhu*. Upregulation of sestrin 2 expression via JNK pathway activation contributes to autophagy induction in cancer cells. Cell Signal. 2013 Jan;25(1):150-8
      14. Rong Deng, Fen Yang, Shao-Hua Chang, Jun Tang, Juan Qin, Gong-Kan Feng, Ke Ding, Xiao-Feng Zhu*. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth. Mol Pharmacol, 2012, 82(2):189-98
      15. Jun Tang, Rong Deng, Rong-Zhen Luo, Guo-Ping Shen, Mo-Yan Cai, Zi-Ming Du, Shang Jiang, Ming-Tian Yang, Jian-Hua Fu, Xiao-Feng Zhu*. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat, 2012, 134(2):549-60
      16. Dan-Dan Li, Ting Sun, Xiao-Qi Wu, Shu-Peng Chen, Rong Deng, Shan Jiang, Gong-Kan Feng, Jin-Xuan Pan, Xiao-shi Zhang, Yi-Xin Zeng, Xiao-Feng Zhu*. The Inhibition of Autophagy Sensitises Colon Cancer Cells with Wild-Type p53 but Not Mutant p53 to Topotecan Treatment. PLoS ONE*, 2012, 7(9): e45058. doi:10.1371/journal.pone.0045058
      17. Fen Yang, Wen-Dan Chen, Rong Deng, Dan-Dan Li, Ke-Wei Wu, Gong-Kan Feng, Hou-Jin Li, Xiao-Feng Zhu*. Hirsutanol A induces apoptosis and autophagy via reactive oxygen species accumulation in breast cancer MCF-7 cells. J Pharmacol Sci, 2012, 119(3):214-20
      18. Wei Qin, Zhen-Mei Lin, Deng R, Dan-Dan Li, Zhi Song, Yi-Guo Tian, RF Wang, JQ Ling, Xiao-Feng Zhu*. p38a MAPK is involved in BMP-2-induced odontoblastic differentiation of human dental pulp cells. Int Endod J, 2012,45(3):224-33
      19. Ning-Ning Zhou, Jun Tang, Wen-Dan Chen, Gong-Kan Feng, Bin-Fen Xie, Zong-Chao Liu, Dajun Yang, Xiao-Feng Zhu*. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells. Life Sci, 2012, 22;90(19-20):770-5
      20. Ting Sun, Dan-Dan Li, Lin-Lin Wang, Liang-Ping Xia, Jian-Guo Ma, Zhong Guan, Gong-Kan Feng, Xiao-Feng Zhu*. c-Jun NH2-terminal kinase activation is essential for up-regulation of LC3 during ceramide induced autophagy in human nasopharyngeal carcinoma cells. J Trans Med, 2011, 9:161
      21. Shan Jiang, Yong Li, Ying-Hui Zhu, Xiao-Qi Wu, Jun Tang, Zheng Li, Gong-Kan Feng, Rong Deng, Dan-Dan Li, Rong-Zhen Luo, Mei-Fang Zhang, Wei Qin, Xin Wang, Wei-Hua Jia, Xiao-Feng Zhu*. Intensive expression of UNC-51-like kinase 1 is a novel biomarker of poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Science, 2011, 102: 1568–1575
      22. Rong Deng, Jun Tang, Jian-Guo Ma, Shu-Peng Chen, Liang-Ping Xia, Wen-Jun Zhou, Dan-Dan Li, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene, 2011, 30: 944-55
      23. Dan-Dan Li, Jin-Feng Guo, Jia-Jia Huang, Lin-Lin Wang, Rong Deng, Jian-Nan Liu, Gong-Kan Feng, Ding-Jun Xiao, Song-Zhi Deng, Xiao-Shi Zhang, Xiao-Feng Zhu*. Rhabdastrellic acid-A induced autophagy-associated cell death through blocking Akt pathway in human cancer cells. PLos One, 2010, 5(8):e12176
      24. Rong Deng, Jun Tang, Bin-Fen Xie, Gong-Kan Feng, Yue-Han Huang, Zong-Chao Liu, Xiao-Feng Zhu*. SYUNZ-16, a new synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of AKT/FOXO signal pathway. Int J Cancer, 2010, 127(1):220-9
      25. Wen-Jun Zhou, Rong Deng, Xiao-Yue Zhang, Gong-Kan Feng, Lian-Quan Gu, Xiao-Feng Zhu*. G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells. Mol Cancer Ther, 2009, 8:3203-3213
      26. Dan-Dan Li, Lin-Lin Wang, Rong Deng, Jun Tang, Yang Shen, Jin-Feng Guo, Yao Wang, Liang-Ping Xia, Gong-Kan Feng, Quentin Q Liu, Wen-Lin Huang, Yi-Xin Zeng, Xiao-Feng Zhu*. The pivotal role of c-Jun-NH2-terminal kinase-mediated Beclin-1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene, 2009, 28, 886-898.
      27. Rong Deng, Jun Tang, Liang-Ping Xia, Dan-Dan Li, Lin-Lin Wang, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. ExcisaninA induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. Mol Cancer Ther, 2009, 8(4): 873-882.
      28. Dan-Dan Li, Xiao-Qi Wu, Ju Tang, Xiao-Yi Wei, Xiao-Feng Zhu*. ON-III inhibits erbB-2 tyrosine kinase receptor signal pathway and triggers apoptosis through induction of Bim in breast cancer cells. Cancer Biol & Ther, 2009; 8(8):739-43
      29. Yuan XW, Zhu XF*, Liang SG, Fan Q, Chen ZX, Huang XF, Sheng PY, He AS, Yang ZB, Deng R, Feng GK, Liao WM. Interferonalpha enhances etoposide-induced apoptosis in human osteosarcoma U2OS cells by a p53-dependent pathway. Life Sci, 2008, 82(7-8): 393-401
      30. Guo JF, Zhou JM, Zhang Y, Deng R, Liu JN, Feng GK, Liu ZC, Xiao DJ, Deng SZ, Zhu XF*. Rhabdastrellic acid-A inhibited PI3K/Akt pathway and induced apoptosis in human leukemia HL-60 cells. Cell Biol Int. 2008, 32(1):48-54
      31. Xiang-Wei Yuan, Xiao-Feng Zhu*, Wei-Ming Liao. p14ARF sensitizes human osteosar- coma cells to cisplatin-induced apoptosis in a p53-independent manner. Cancer Biology & Therapy, 2007, 6(7): 1074 -1080
      32. Xiang-Wei Yuan, Xiao-Feng Zhu*, Huang XF, Sheng PY, He AS, Yang ZB, Deng R, Feng GK, Liao WM. Interferon-alpha enhances sensitivity of human osteosarcoma U2OS cells to doxorubicin by p53-dependent apoptosis1. Acta Pharmacol Sin, 2007, 28(11):1835-41.
      33. Yu-Ping Mei, Jun-Min Zhou, Yi Wang, He Huang, Rong Deng, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle, 2007, 6(11): 1379-1385.
      34. Jian-nan Liu, Rong Deng, Jin-Feng Guo, Jun-Min Zhou, Gong-Kan Feng, Zhi-Shu Huang, Lian-Quan Gu, Yi-Xin Zeng, Xiao-Feng Zhu*. Inhibition of myc promoter and telomerase activity and induction of delayed apoptosis by SYUIQ-5, a novel G-quadruplex interactive agent in leukemia cells. Leukemia, 2007, 21(6), 1300-1302
      35. Zhi-Yi Cheng, Wen-Jie Li, Feng He, Jun-Min Zhou and Xiao-Feng Zhu*. Synthesis and biological evaluation of 4-aryl-5-cyano-2H-1,2,3-triazoles as inhibitor of HER2 tyrosine kinase. Bioorg Med Chem, 2007, 15(3): 1533-1538
      36. Rong Deng, Wenming Li, Zhong Guan, Jun-Min Zhou, Yi Wang, Yu-Ping Mei, Ming-Tao Li, Gong-Kan Feng, Wenlin Huang, Zong-Chao Liu, Yifan Han, Yi-Xin Zeng and Xiao-Feng Zhu*. Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis. Oncogene, 2006, 25(53):7070-7
      37. Jun-Min Zhou, Xiao-Feng Zhu*, Yu-Jin Lu, Rong Deng, Zhi-Shu Huang, Yu-Ping Mei, Yi Wang, Wenlin Huang, Zong-Chao Liu, Lian-Quan Gu and Yin-Xin Zeng. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene, 2006, 25, 503-511
      38. Yu-Ping Mei, Xiao-Feng Zhu*, Jun-Min Zhou, He Huang, Rong Deng, Yi-Xin Zeng. siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression. Cancer Letters, 2006, 232, 189-198
      39. Jin-Jun Zhu, Fu-Bo Li, Xiao-Feng Zhu*, Wei-Ming Liao. The p33(ING1b) tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells. Life Sciences, 2006, 78(13):1469-77
      40. Jin-Jun Zhu, Fu-Bo Li, Jun-Min Zhou, Zong-Chao Liu, Xiao-Feng Zhu*, Wei-Ming Liao. The Tumor Suppressor p33(ING1b) Enhances Taxol-induced Apoptosis by p53-Dependent Pathway in Human Osteosarcoma U2OS Cells. Cancer Biol Ther, 2005, 4(1):39-47.
      41. Zong-Wei Wang, Jun-Min Zhou, Zhi-Shu Huang, Ai-Ping Yang, Zong-Chao Liu, Yun-Fei Xia, Yi-Xin Zeng, Xiao-Feng Zhu*. Aloe polysaccharides mediated radioprotective effect through the inhibition of apoptosis. J Radiat Res, 2004, 45 (3): 447-454.
     
    主编的专著
      1) 《信号转导与疾病》,2012年5月人民卫生出版社出版,(黄文林,朱孝峰主编)
      2) 《肿瘤生物治疗学》,2005,12,广东科技出版社,(姜文奇,张晓实,朱孝峰,李志铭主编)
      3) 《肿瘤分子靶向治疗》,2009,5,人民卫生出版社,(朱孝峰,副主编)
      4) 《黑色素瘤基础与临床》,2010,11,人民卫生出版社,(朱孝峰,副主编)
      5) 《肿瘤360》,2014,10,凤凰科学技术出版社,(朱孝峰,副主编)
    申请的专利
      1. 5-噻唑酰胺类化合物及生物学应用,2010.10,中国,ZL2010102651155。
      2. 一种抗肿瘤化合物Chondrosterin J 及其制备方法与运用, 2013.12 , 中国,201310692093.4。
      3. Hirsutanols A 在制备抗肿瘤药物中的应用,2009.10,中国,ZL200910037541.0。
      4. 紫草萘醌类衍生物及其在制备抗癌药物中的应用。中国专利号:ZL02114973.9
      5. 脂肪氨基取代喹啉衍生物及其制备方法和制药用途。中国专利号:ZL200310112457.3;国际专利申请号:PCT/CN2004/000175。
      6. Houttuyninum compositions and methods for inhibiting the activity of erbB-2 based thereon. 国际专利申请号:PCT/US01/43123。
      7. 碘化-3,3’-二乙基-9-甲基-硫杂羰花青的抗肿瘤新用途。中国专利申请号:02134263.6。
      8. 人表皮生长因子受体2酪氨酸激酶抑制剂。 中国专利申请号:200410052496.3
      9. 一种查尔酮肟及其组合物、制备方法和应用。中国专利号:ZL200510101717.6

                更新时间:2017.2.13

访客通道
员工通道
关注肿瘤医院
留言建议 ×